

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice

New Programs

- **UGIBPEMI** Pemigatinib for Advanced FGFR2 Mutation-Positive Cholangiocarcinoma
- **GIGAVCOXZ** Zolbetuximab, Capecitabine and Oxaliplatin for Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma
- **GIGAVFFOXZ** Zolbetuximab, Fluorouracil and Oxaliplatin for Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma
- **GUOTSUNI** Sunitinib for Malignant Pheochromocytoma and Secretory Paraganglioma
- **Myeloid Tumour Group Announcement**
- **UMLASMAVA** Avapritinib in Advanced Systemic Mastocytosis
- **UMLMFMOM** Mometinib in Symptomatic Myelofibrosis

Practice Standards and Policies

- Dose Banding
- Frozen Gloves
- Provincial Systemic Therapy Policy Documents

Cancer Drug Manual®

New

avapritinib, momelotinib, pembrolizumab, sunitinib, zolbetuximab

Chemotherapy Preparation and Stability Chart abbreviations, mesna, oxaliplatin, pembrolizumab

Cancer Drug Manual® (continued)

IV Bag Size & Vial Selection zolbetuximab

Oncology High-Alert Medications avapritinib, momelotinib, zolbetuximab

CDM Acknowledgements

Continuing Education

Family Practice Oncology Network

Benefit Drug List

New UGIBPEMI, GIGAVCOXZ, GIGAVFFOXZ, GUOTSUNI, UMLASMAVA, UMLMFMOM

Revised GIRCAP, Pediatric: nivolumab

Protocols, PPPOs and Patient Handouts

New GI UGIBPEMI, GIGAVCOXZ, GIGAVFFOXZ **GU** GUOTSUNI **ML** UMLASMAVA, UMLMFMOM

Revised BR GIBRAVNAV, BRAVPTRVIN **CN** CNMODPCV **GI** GIGAVRAMT, GIRCAP **GO** GOOVBEVV, GOOVVIN, GOTDEMACO **GU** GUNAJPG **HN** HNOTVAN, HNSAVNP **LU** LUJNP, LUAVNP, LUAVPEM, LUAVPMTN, LUAVPP, LUAVPPIPNI, LUAVPPMBM, LUAVPPMB, LUAVVIN, LUMMPP, LUMMVIN, LUOTCAV, LUSCCAV **LY** LYCHOP, LYCHOPO, LYCHOPR, LYCHOPRMTX, LYCLCVPR, LYCODOXMR, LYCVP, LYCVPO, LYCVPPABO, LYCVPR, LYGVLD **SA** KSVB, SAVAC, SAVDC

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 January 2026. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Gastrointestinal

Pemigatinib for Advanced FGFR2 Mutation-Positive Cholangiocarcinoma (UGIBPEMI) – The BC Cancer Gastrointestinal Tumour Group is implementing pemigatinib for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with an *FGFR2* fusion or other rearrangement. Though *FGFR2* genetic alterations are uncommon, they are one of the most frequent genetic alternations seen in patients with intrahepatic CCA. Ocular and nail toxicities are reported with

Editor's Choice

pemigatinib; comprehensive eye examination and monitoring by ophthalmology or optometry is strongly recommended. For more information on pemigatinib, see the Cancer Drug Manual section in this issue. BC Cancer Compassionate Access Program (CAP) approval is required.

Treatment program approval is supported by evidence from the single-arm, open-label, phase II FIGHT-202 trial. In this trial, treatment with pemigatinib demonstrated durable response and prolonged overall survival in patients with previously treated, unresectable locally advanced or metastatic CCA with an *FGFR2* fusion or other rearrangement.^{1,2} The most reported treatment-emergent adverse events were hyperphosphatemia, alopecia and diarrhea.

Zolbetuximab, Fluoropyrimidine and Oxaliplatin for Locally Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Carcinoma (GIGAVCOXZ, GIGAVFFOXZ) – The BC Cancer Gastrointestinal Tumour Group is implementing treatment with zolbetuximab in combination with fluoropyrimidine-oxaliplatin chemotherapy in patients with previously untreated locally advanced unresectable or metastatic gastric, gastroesophageal (GEJ) or esophageal carcinoma. The tumour must be HER2-negative and positive for the Claudin18 isoform 2 (CLDN18.2) protein. Zolbetuximab is a monoclonal antibody that targets and binds to CLDN18.2 on the surface of malignant gastric mucosal cells, activating the complement cascade and immune effector cells to kill CLDN18.2-positive cells. Based on the rates of nausea and vomiting with zolbetuximab in combination with chemotherapy, these protocols are considered highly emetogenic. In addition, infusion-related reactions and hypersensitivity reactions have been reported with zolbetuximab. To minimize nausea, vomiting and infusion-related reactions, each zolbetuximab infusion requires rate titration using the rate titration tables for the loading and maintenance doses provided in the protocols.

The randomized, placebo-controlled phase III GLOW and SPOTLIGHT trials demonstrated that zolbetuximab, when added to fluoropyrimidine-oxaliplatin chemotherapy, resulted in added clinical benefit for patients with locally advanced unresectable or metastatic HER2-negative and CLDN18.2-positive gastric or GEJ carcinoma.³⁻⁵ The trials demonstrated statistically significant and clinically meaningful improvements in overall survival and progression-free survival with zolbetuximab compared to chemotherapy alone. Treatment with zolbetuximab in combination with chemotherapy was shown to be associated with an increased risk of nausea, vomiting, and infusion-related reactions, when compared with chemotherapy alone.

Genitourinary

Sunitinib for Malignant Pheochromocytoma and Secretory Paraganglioma (GUOTSUNI) – The BC Cancer Genitourinary Tumour Group is implementing treatment with sunitinib for patients with unresectable malignant pheochromocytoma or secretory paraganglioma. Malignant pheochromocytoma and secretory paraganglioma are extremely rare neuroendocrine tumours; these tumours are highly symptomatic from hormone secretion and carry a poor prognosis. The phase II SNIPP and FIRSTMAPPP trials investigated the role of sunitinib in patients with progressive paraganglioma or pheochromocytoma, with sunitinib demonstrating progression-free survival benefit.^{6,7} Until now systemic therapy options have been limited with no standard therapy available in British Columbia, therefore sunitinib represents a much-needed treatment option.

Myeloid

The **Myeloid Tumour Group** has been formally established, with Dr. Lynda Foltz as Tumour Group Chair. Treatment protocol codes will use **ML** as the designated abbreviation/suffix. The Myeloid Tumour Group

Editor's Choice

protocols webpage will be available on the BC Cancer website as of 01 January 2026. The webpage will include the new Myeloid Tumour Group protocols for avapritinib in advanced systemic mastocytosis and momelotinib in myelofibrosis, as well as links to relevant protocols of the Leukemia & BMT Tumour Group.

Avapritinib in Advanced Systemic Mastocytosis (UMLASMAVA) – The BC Cancer Myeloid Tumour Group is introducing avapritinib for the treatment of patients with advanced systemic mastocytosis (AdvSM), a rare hematological malignancy characterized by the proliferation and accumulation of clonal mast cells. Symptoms are related to the release of mast cell mediators and mast cell tissue infiltration. In most patients, AdvSM is driven by the *KIT* D816V mutation. Avapritinib is an oral tyrosine kinase inhibitor with high selectivity and potency for KIT D816V-mutated proteins. BC Cancer Compassionate Access Program (CAP) approval is required.

The phase II PATHFINDER trial in patients with AdvSM on first or subsequent lines of therapy showed rapid and durable responses with avapritinib.⁸⁻¹⁰ Treatment with avapritinib demonstrated measurable improvement in quality of life scores and reduction in disease specific symptom scores. The most frequent grade ≥ 3 adverse events were neutropenia, thrombocytopenia and anemia.

Momelotinib in Symptomatic Myelofibrosis (UMLMFOM) – The BC Cancer Myeloid Tumour Group is also introducing momelotinib for the treatment of patients with symptomatic primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF. Myelofibrosis is a rare and chronic hematological malignancy characterized by dysregulated Janus kinase (JAK)-mediated signalling, bone marrow fibrosis, bone marrow failure and systemic inflammation. Key clinical manifestations of MF include progressive anemia, thrombocytopenia, hepatosplenomegaly, and constitutional symptoms. Momelotinib is an oral inhibitor of JAK1 and JAK2, as well as an inhibitor of activin A receptor type 1 (ACVR1), a key regulator of iron metabolism. BC Cancer Compassionate Access Program (CAP) approval is required.

The randomized, phase III MOMENTUM trial focused on patients with symptomatic and anemic MF who had received prior JAK inhibitor therapy.^{11,12} The trial demonstrated that treatment with momelotinib, compared with danazol, resulted in clinically significant improvements in MF-related symptoms, anemia measures, spleen response and transfusion dependency. Thrombocytopenia and anemia were the most common grade 3 or 4 adverse events. In the prior randomized, phase III SIMPLIFY-1 trial in patients with MF who had not previously received JAK inhibitor therapy, momelotinib treatment was associated with a reduced transfusion requirement compared to ruxolitinib.¹³

References:

1. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Pemigatinib (Pemazyre®). *Canadian Journal of Health Technologies* 2025;5(5):1-25. <https://doi.org/10.51731/cjht.2025.1132>
2. Vogel A, Sahai V, Hollebecque A, et al. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. *ESMO Open* 2024;9(6):1-11. <https://doi.org/10.1016/j.esmoop.2024.103488>
3. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Zolbetuximab (Vyloy®). *Canadian Journal of Health Technologies* 2025; 5(2):1-30. <https://doi.org/10.51731/cjht.2025.1077>
4. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. *Nat Med* 2023;29(8):2133-2141. <https://doi.org/10.1038/s41591-023-02465-7>
5. Shitara K, Lordick F, Bang Y-J, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *Lancet* 2023;401(10389):1655-1668. [https://doi.org/10.1016/S0140-6736\(23\)00620-7](https://doi.org/10.1016/S0140-6736(23)00620-7)
6. O'Kane GM, Ezzat S, Joshua AM, et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. *Br J Cancer* 2019;120(12):1113-1119. <https://doi.org/10.1038/s41416-019-0474-x>
7. Baudin E, Goichot B, Berruti A, et al. Sunitinib for metastatic progressive pheochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet* 2024;403(10431):1061-1070. [https://doi.org/10.1016/S0140-6736\(23\)02554-0](https://doi.org/10.1016/S0140-6736(23)02554-0)
8. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Avapritinib (Ayyakyt®). *Canadian Journal of Health Technologies* 2024;4(11):1-25. <https://doi.org/10.51731/cjht.2024.1028>

Editor's Choice

9. Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. *Nat Med* 2021;27(12):2192-2199. <https://doi.org/10.1038/s41591-021-01539-8>
10. Reiter A, Schwaab J, DeAngelo DJ, et al. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. *Blood Adv* 2022;6(21):5750-5762. <https://doi.org/10.1182/bloodadvances.2022007539>
11. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Momelotinib (Ojjaara®). *Canadian Journal of Health Technologies* 2025;5(2): 1-28. <https://doi.org/10.51731/cjht.2025.1075>
12. Verstovsek, S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. *Lancet* 2023;401(10373):269-280. [https://doi.org/10.1016/S0140-6736\(22\)02036-0](https://doi.org/10.1016/S0140-6736(22)02036-0)
13. Mesa RA, Kiladjian J-J, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. *J Clin Oncology* 2017, 35(34): 3844-3850. <https://doi.org/10.1200/JCO.2017.73.4418>

Practice Standards and Policies

All Systemic Therapy policies and procedures are on the BC Cancer page of [Shared Health Organizations Portal \(SHOP\)](#).

Dose Banding

As part of the dose banding expansion at BC Cancer:

- dose bands for capecitabine and temozolomide were integrated into all protocols and PPPOs in November; as such, the 'Capecitabine Suggested Tablet Combination Table' and 'Temozolomide Suggested Capsule Combination Table' are now being removed from the Cancer Drug Manual Index
- dose banding will continue with durvalumab, paclitaxel NAB and pembrolizumab in February 2026
- Systemic Therapy [Procedure III-140: Management of Dose Banded Cancer Drug Treatments](#) will be updated as needed to reflect drugs approved for dose banding

Frozen Gloves

Professional Practice Nursing has implemented a [Frozen Gloves Procedure](#), which guides the safe application and monitoring of frozen gloves during docetaxel administration. The document supports the use of frozen glove cryotherapy while prioritizing patient safety, with a goal of minimizing cold-related injuries and maximizing protection against systemic therapy-related nail and skin toxicities. To accompany the procedure, a patient handout entitled [Using Frozen Gloves at BC Cancer](#) was created.

Provincial Systemic Therapy Policy Documents

Provincial Systemic Therapy has revised the following policies as part of a routine review:

- [Policy III-90: Parenteral Drug Therapy](#)
 - minor changes
- [Policy III-230: Scalp Cooling Systems and Cold Caps for Chemotherapy-Induced Alopecia](#)
 - the term "cooling systems" was changed to "scalp cooling systems"
 - information about battery-powered scalp cooling systems was added

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

New Documents

The **Pemigatinib Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Theresa Chan (medical oncologist, BC Cancer Gastrointestinal Tumour Group), Dr. Cheryl Ho (medical oncologist, BC Cancer – Vancouver), and Jelena Mucovic (oncology drug information specialist, BC Cancer Provincial Pharmacy). Pemigatinib is an orally administered kinase inhibitor that selectively targets fibroblast growth factor receptor (FGFR) 1, 2 and 3. It is used in the treatment of cholangiocarcinoma with an *FGFR2* mutation. The usual dose is 13.5 mg once daily for 14 consecutive days, followed by 7 days rest, in a 21-day cycle, following BC Cancer Protocol UGIBPEMI.

Highlights from these documents include:

- hyperphosphatemia is an on-target effect of FGFR inhibition that commonly occurs with pemigatinib; dietary management may be required
- serous retinal detachment is reported; ophthalmologic exams are recommended prior to starting treatment and should be regularly repeated during treatment
- patients with pre-existing severe renal or hepatic impairment require starting dose reduction

Pemigatinib has been added to the **Auxiliary Label List** and was evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Avapritinib Monograph and Patient Handout

Header and Footer: removed “interim” designation

Dosage Guidelines: added new BC Cancer protocol (UMLASMAVA); bolded and italicized BC Cancer standard dosing

Patient Handout: removed “interim” designation from Header and Footer

Momelotinib Monograph and Patient Handout

Header and Footer: removed “interim” designation

Dosage Guidelines: added new BC Cancer protocol (UMLFMOM); bolded and italicized BC Cancer standard dosing

Patient Handout: removed “interim” designation from Header and Footer

Pembrolizumab Chemotherapy Preparation and Stability Chart

Product Stability: updated stability

Special Precautions: updated to include information about room temperature storage and presence of particles

Sunitinib Monograph and Patient Handout

Uses: added pheochromocytoma

Cautions: added impaired wound healing; updated *Carcinogenicity, Fertility, and Pregnancy*

Side Effects: added thrombotic angiopathy and cerebrovascular events to table

Supply and Storage: updated available brands

Cancer Drug Manual[©]

Dosage Guidelines: added BC Cancer protocols (GIPNSUNI, GUOTSUNI, GUSUNI and SAAVGS); bolded and italicized BC Cancer standard dosing; removed statement about Appendix under myelosuppression; updated hepatic impairment; updated formatting and style according to template

Patient Handout (throughout): updated template wording

Zolbetuximab Monograph and Patient Handout

Header and Footer: removed “interim” designation

Dosage Guidelines: added new BC Cancer protocol (GIGAVFFOXZ); bolded and italicized BC Cancer standard dosing

Patient Handout: removed “interim” designation from Header and Footer

Chemotherapy Preparation and Stability Chart

Chemotherapy Preparation and Stability Chart

Abbreviations: expanded list of abbreviations following chart

Mesna: revised final concentration to include upper limit in *Product* column for both available brands

Oxaliplatin: added Fresenius Kabi as new brand

Pembrolizumab: updated *Product Stability* column to include extended stability for Merck brand

IV Bag Size & Vial Selection

Zolbetuximab has been added to the [IV Bag Size Selection](#) table.

Oncology High-Alert Medications List

Avapritinib, **pemigatinib** and **zolbetuximab** have been added to the [Oncology High-Alert Medications List](#).

CDM Acknowledgements

The Cancer Drug Manual Editor, Nadine Badry (BC Cancer – Victoria), and Writer, Amy Lim (BC Cancer – Abbotsford), would like to gratefully acknowledge the contributions of the CDM Editorial Review Board and expert reviewers for the year 2025. Thank you for your ongoing support of the CDM and for generously sharing your time and expertise throughout the year.

Editorial Board

Physicians

Angela Chan, BC Cancer – Surrey
Maria Ho, BC Cancer – Prince George

Nurses

Megan Crosby, BC Cancer – Prince George
Brittany Freeman, BC Cancer – Prince George
Michelle Lafreniere, BC Cancer – Victoria
Stephanie Townsend, BC Cancer – Kelowna

Pharmacists

Anne Dar Santos, BC Cancer – Provincial Pharmacy
Jennifer Kendrick, BC Children's Hospital
Khushminder Rai, BC Cancer – Surrey
Jennifer Suess, BC Cancer – Abbotsford

Expert Reviewers

Physicians

Theresa Chan, BC Cancer – Surrey
Lynda Foltz, St. Paul's Hospital
Donna Forrest, Vancouver General Hospital
Cheryl Ho, BC Cancer – Vancouver
Howard Lim, BC Cancer – Vancouver
Harvey Lui, The Skin Care Centre, Vancouver
Krista Noonan, BC Cancer – Surrey
David Sanford, Vancouver General Hospital
Laurie Sehn, BC Cancer – Vancouver

Pharmacists

Jelena Mucovic, BC Cancer – Provincial Pharmacy
Robert Tillmanns, BC Cancer – Provincial Pharmacy

Continuing Education

Family Practice Oncology Network

The Family Practice Oncology Network (FPON) is pleased to announce a webinar with Dr. Charlotte Yong-Hing on **Breast Cancer Screening and Breast Density**. The webinar is happening on Thursday 15 January 2026, from 0800-0900h, as part of the accredited, complimentary FPON webcasts.

By the end of the session, participants will be able to:

- Describe current BC breast screening guidelines
- Summarize imaging challenges for patients with dense breasts
- Discuss the role of additional screening technologies

For more information and link to registration, visit:

[UBC CPD | FPON Webinar: Breast Cancer Screening and Breast Density](#)

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 January 2026:

Protocol Title	Protocol Code	Benefit Status
Therapy of Advanced FGFR2 Mutation-Positive Cholangiocarcinoma using Pemigatinib	UGIBPEMI	Restricted
Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Carcinoma using Capecitabine, Oxaliplatin and Zolbetuximab	GIGAVCOXZ	Class I
Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Carcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Zolbetuximab	GIGAVFFOXZ	Class I
Treatment of Malignant Pheochromocytoma and Secretory Paraganglioma using Sunitinib	GUOTSUNI	Class I
Treatment of Advanced Systemic Mastocytosis using Avapritinib	UMLASMAVA	Restricted
Treatment of Symptomatic Myelofibrosis with Momelotinib	UMLMFMOM	Restricted

Benefit Drug List

Revised Programs

The following treatment programs have been revised on the BC Cancer [Benefit Drug List](#) effective 01 January 2026:

Protocol Title	Protocol Code	Benefit Status
Adjuvant Therapy for Stage II and III Rectal Cancer using Capecitabine in Patients Previously Treated with Preoperative Radiation or Chemoradiation Therapy Alone	GIRCAP	Class I
Treatment of pediatric patients (12 years and older) with bulky stage II, stage IIb to and IV Hodgkin lymphoma using 6 cycles of nivolumab with doxorubicin, vinblastine and dacarbazine	Pediatric	Class I

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked ☑*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
UGIBPEMI	Therapy of Advanced FGFR2 Mutation-Positive Cholangiocarcinoma using Pemigatinib	☑	☑	<input type="checkbox"/>
GIGAVCOXZ	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Carcinoma using Capecitabine, Oxaliplatin and Zolbetuximab	☑	☑	<input type="checkbox"/>
GIGAVFFOXZ	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Carcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Zolbetuximab	☑	☑	<input type="checkbox"/>
GUOTSUNI	Treatment of Malignant Pheochromocytoma and Secretory Paraganglioma using Sunitinib	☑	☑	<input type="checkbox"/>
UMLASMAVA	Treatment of Advanced Systemic Mastocytosis using Avapritinib	☑	☑	<input type="checkbox"/>
UMLMF MOM	Treatment of Symptomatic Myelofibrosis with Momelotinib	☑	☑	<input type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAVNAV	Palliative Therapy for Metastatic Breast Cancer using Vinorelbine	<i>Bag size and Contact Physician updated; Treatment and Tests clarified</i>	<i>Bag size updated; tests and treatment clarified</i>	---
BRAVPTRVIN	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Vinorelbine as First-Line Treatment for Advanced Breast Cancer	<i>Bag size and Contact Physician updated; Tests, Dose Modifications and units of measure clarified</i>	<i>Bag size updated; tests, treatment and units of measure clarified</i>	---
CN Neuro-Oncology				

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
CNMODPCV	Modified PCV Chemotherapy of Brain Tumours using Procarbazine, Lomustine (CCNU) and Vincristine	<i>Bag size and Contact Physician updated; Tests, Dose Modifications and units of measure clarified</i>	<i>Bag size updated; tests and Return Appointment Orders clarified</i>	---
GI Gastrointestinal				
GIGAVRAMT	Second- or Third-Line Therapy for Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer using Weekly Paclitaxel and Ramucirumab	<i>Eligibility clarified</i>	---	---
GIRCAP	Adjuvant Therapy for Stage II and III Rectal Cancer using Capecitabine in Patients Previously Treated with Preoperative Radiation or Chemoradiation Therapy Alone	<i>Protocol title and Eligibility updated; Exclusions removed</i>	---	---
GO Gynecologic Oncology				
GOOVBEVV	Treatment of Platinum-Resistant or -Refractory Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine	<i>Bag size and Premedications updated; Tests, Treatment and Dose Modifications clarified</i>	---	---
GOOVVIN	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma using Vinorelbine	<i>Bag size and Premedications updated: Eligibility, Treatment and Dose Modifications clarified</i>	<i>Bag size updated; treatment and tests clarified</i>	---
GOTDEMACO	Therapy for High-Risk Gestational Trophoblastic Neoplasia (GTN) using Etoposide, Methotrexate, Leucovorin (Folinic Acid), Dactinomycin, Cyclophosphamide and Vincristine	<i>Bag size updated; hyperlink added; Tests and units of measure clarified</i>	<i>Bag size updated; tests and units of measure clarified</i>	---
GU Genitourinary				
GUNAJPG	Neo-Adjuvant Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine	---	---	<i>Carboplatin option removed</i>
HN Head and Neck				
HNOTVAN	Treatment for Locally Advanced or Metastatic Medullary Thyroid Cancer using Vandetanib	<i>Premedications updated; Contact Physician, Eligibility, Exclusion, Tests, Dose Modifications and Precautions clarified</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
HNSAVNP	Palliative Treatment of Advanced Salivary Gland Cancers with Cisplatin and Vinorelbine	<i>Bag size, Premedications and Contact Physician updated; Eligibility, Tests and units of measure clarified</i>	<i>Bag size updated; tests, treatment and units of measure clarified</i>	---
LU Lung				
LUAJNP	Adjuvant Cisplatin and Vinorelbine Following Resection of Non-Small Cell Lung Cancer	<i>Bag size and Contact Physician updated; Tests, Treatment and units of measure clarified</i>	<i>Bag size updated; units of measure clarified</i>	---
LUAJPP	Adjuvant Treatment of Non-Small Cell Lung Cancer with Cisplatin and Pemetrexed	---	---	<i>Weekly blood tests removed</i>
LUAVNP	Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Vinorelbine	<i>Bag size, Premedications and Contact Physician updated; Eligibility, Tests and Treatment clarified</i>	<i>Bag size updated; tests and treatment clarified</i>	---
LUAVPEM	Second-Line Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed	---	---	<i>Weekly blood tests removed</i>
LUAVPMTN	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with Pemetrexed	---	---	<i>Weekly blood tests removed</i>
LUAVPP	Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Pemetrexed	---	---	<i>Weekly blood tests removed</i>
LUAVPPIPNI	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	---	---	<i>Weekly blood tests removed</i>
LUAVPPMBM	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with Pemetrexed and Pembrolizumab	---	---	<i>Weekly blood tests removed</i>
LUAVPPMB	Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, and Pembrolizumab	---	---	<i>Weekly blood tests removed</i>
LUAVVIN	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Vinorelbine in Elderly Patients	<i>Bag size and Contact Physician updated; Eligibility, Tests and Treatment clarified</i>	<i>Bag size updated; treatment and tests clarified</i>	---
LUMMPP	Treatment of Malignant Mesothelioma with Cisplatin and Pemetrexed	---	---	<i>Weekly blood tests removed</i>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LUMMVIN	Treatment of Malignant Mesothelioma with Vinorelbine	<i>Bag size and Contact Physician updated; Eligibility, Tests and Treatment clarified</i>	<i>Bag size updated; treatment and tests clarified</i>	---
LUOTCAV	Treatment of Thymoma/Thymic Carcinoma with Cyclophosphamide, Doxorubicin and Vincristine (CAV)	<i>Bag size and Contact Physician updated; Eligibility, Tests and Treatment clarified</i>	<i>Bag size updated; tests and infusion time clarified</i>	---
LUSCCAV	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Cyclophosphamide, Doxorubicin and Vincristine (CAV)	<i>Bag size and Physician Contact updated; Eligibility, Tests and infusion time clarified</i>	<i>Bag size updated; tests, treatment and infusion time clarified</i>	---
LY Lymphoma				
LYCHOP	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine and Prednisone (CHOP)	<i>Bag size updated; Tests, route of administration and infusion time clarified; TALLman lettering added</i>	<i>Bag size updated; tests and infusion time clarified</i>	---
LYCHOPO	Treatment of Rituximab-Refractory Follicular Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Obinutuzumab	<i>Bag size updated; Treatment and units of measure clarified; TALLman lettering added</i>	Induction Cycle 1 <i>Bag size updated; units of measure clarified</i> Induction Cycles 2 to 6 <i>Bag size updated; units of measure and Treatment clarified</i>	---
LYCHOPR	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (CHOP-R)	<i>Bag size updated; units of measure clarified; hyperlink and TALLman lettering added</i>	<i>Bag size and tests updated; units of measure clarified</i>	---
LYCHOPRMTX	Central Nervous System Prophylaxis with High-Dose Methotrexate, CHOP and Rituximab in Diffuse Large B-Cell Lymphoma	<i>Bag size updated; Contact Physician, Eligibility, Tests, units of measure and Dose Modifications clarified</i>	<i>Bag size updated; tests and units of measure clarified</i>	---
LYCLLCVPR	Treatment of Relapsed Chronic Lymphocytic Leukemia using Cyclophosphamide, Vincristine, Prednisone and Rituximab (CVP-R)	<i>Bag size updated; Tests and units of measure clarified</i>	<i>Bag size updated; units of measure clarified</i>	---
LYCODOXMR	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Leucovorin (CODOX-M) and Rituximab	<i>Bag size updated; Tests, Premedications, Supportive Medications and units of measure clarified</i>	<i>Bag size updated; tests, administration guidelines and units of measure clarified</i>	---
LYCVP	Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, Vincristine, Prednisone (CVP)	<i>Bag size updated; infusion time and Tests clarified</i>	<i>Bag size updated; tests, treatment and infusion time clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LYCVPO	Treatment of Rituximab-Refractory Follicular Lymphoma with Cyclophosphamide, Vincristine, Prednisone and Obinutuzumab	<i>Bag size updated; Tests, Treatment and units of measure clarified</i>	Induction Cycle 1 and Induction Cycles 2 to 6 <i>Bag size updated; units of measure clarified</i>	---
LYCVPPABO	Treatment of Hodgkin Lymphoma with Cyclophosphamide, Vinblastine, Procarbazine, Prednisone, Doxorubicin, Vincristine and Bleomycin	<i>Bag size updated, tests, units of measure and dose modifications clarified, TALLman lettering added</i>	<i>Bag size updated; tests, treatment and units of measure clarified</i>	---
LYCVPR	Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, Vincristine, Prednisone and Rituximab (CVP-R)	<i>Bag size updated; Tests and units of measure clarified</i>	<i>Bag size updated; units of measure clarified</i>	---
LYGVLD	Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and Doxorubicin Pegylated Liposomal	<i>Bag size and Contact Physician updated; Eligibility, Tests and units of measure clarified</i>	<i>Bag size updated; tests, treatment and units of measure clarified</i>	---
SA Sarcoma				
KSVB	Palliative Therapy for Kaposi's Sarcoma using Vinblastine Alternating with Vincristine	<i>Bag size and Contact Physician updated; Eligibility, Tests, and Premedications clarified</i>	<i>Bag size updated; tests and treatment clarified</i>	---
SAVAC	Treatment of Sarcomas with Vincristine, Doxorubicin and Cyclophosphamide (SAVAC)	<i>Bag size updated; Eligibility and Treatment clarified</i>	<i>Bag size updated; tests clarified</i>	---
SAVDC	Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide	<i>Bag size updated, eligibility, tests and units of measure clarified, hyperlink added</i>	<i>Bag size updated; tests clarified</i>	---

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Network	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	mclin@bccancer.bc.ca BCCancerPPNAdmin@phsa.ca ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
 Jelena Mucovic, BScPharm (Assistant Editor)
 Mario de Lemos, PharmD, MSc(Oncol)
 Jeevan Dosanjh, RN, BScN, MN

Alina Gerrie, MD, MPH, FRCPC
 Alison Pow, BScPharm
 Yuna Jang, RN